These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9687402)

  • 21. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.
    Piddock LJ; Johnson M; Ricci V; Hill SL
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2956-60. PubMed ID: 9797232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada.
    Zhanel GG; Walkty A; Nichol K; Smith H; Noreddin A; Hoban DJ
    Diagn Microbiol Infect Dis; 2003 Jan; 45(1):63-7. PubMed ID: 12573552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
    Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
    J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of Ile-460-Val/ParE substitution in clinical Streptococcus pneumoniae isolates that were less susceptible to fluoroquinolones.
    Kawamura-Sato K; Hasegawa T; Torii K; Ito H; Ohta M
    Curr Microbiol; 2005 Jul; 51(1):27-30. PubMed ID: 15942701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
    Iraurgui P; Torres MJ; Aznar J
    Enferm Infecc Microbiol Clin; 2012 Apr; 30(4):180-3. PubMed ID: 22365183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
    Gillespie SH; Voelker LL; Ambler JE; Traini C; Dickens A
    Microb Drug Resist; 2003; 9(1):17-24. PubMed ID: 12705679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.
    Pan XS; Ambler J; Mehtar S; Fisher LM
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2321-6. PubMed ID: 8891138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.
    Varon E; Janoir C; Kitzis MD; Gutmann L
    Antimicrob Agents Chemother; 1999 Feb; 43(2):302-6. PubMed ID: 9925523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.
    Tankovic J; Perichon B; Duval J; Courvalin P
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2505-10. PubMed ID: 8913454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae.
    Piddock LJ; Johnson MM
    Antimicrob Agents Chemother; 2002 Mar; 46(3):813-20. PubMed ID: 11850266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    Pan XS; Fisher LM
    J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.
    Heaton VJ; Goldsmith CE; Ambler JE; Fisher LM
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2998-3000. PubMed ID: 10582896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance of Stenotrophomonas maltophilia to Fluoroquinolones: Prevalence in a University Hospital and Possible Mechanisms.
    Jia W; Wang J; Xu H; Li G
    Int J Environ Res Public Health; 2015 May; 12(5):5177-95. PubMed ID: 25985315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
    Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular characterisation of the quinolone resistance-determining regions (QRDR) including gyrA, gyrB, parC and parE genes in Streptococcus pneumoniae.
    Kakinuma Y; Maeda Y; Mason C; Goldsmith CE; Coulter WA; Matsuda M; Dooley JS; Lowery CJ; Moore JE
    Br J Biomed Sci; 2012; 69(3):123-5. PubMed ID: 23057160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involvement of the putative ATP-dependent efflux proteins PatA and PatB in fluoroquinolone resistance of a multidrug-resistant mutant of Streptococcus pneumoniae.
    Marrer E; Schad K; Satoh AT; Page MG; Johnson MM; Piddock LJ
    Antimicrob Agents Chemother; 2006 Feb; 50(2):685-93. PubMed ID: 16436727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of patA and patB, which encode ABC transporters, is associated with fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
    Garvey MI; Baylay AJ; Wong RL; Piddock LJ
    Antimicrob Agents Chemother; 2011 Jan; 55(1):190-6. PubMed ID: 20937787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.